Mendra is a venture-backed rare-disease biopharma accelerating the development and commercialization of de-risked breakthrough therapies.
Total raised: $82M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.01.2026 | Series A | $82M | 5AM Ventur... |
Mentions in press and media 4
| Date | Title | Description |
| 25.01.2026 | Mendra Revolutionizes Rare Disease Therapy with $82M AI-Driven Launch | Mendra, a San Francisco biopharmaceutical firm, launched with an oversubscribed $82 million Series A funding round. This capital infusion propels its mission. Mendra focuses on rare disease therapies. The company leverages advanced AI. It t... |
| 23.01.2026 | Mendra Launched With $82 Million Series A To Build AI-Enabled Rare Disease Therapeutics Portfolio | Mendra, a newly launched biopharmaceutical company focused on rare diseases, has closed an oversubscribed $82 million Series A to acquire, develop, and commercialize therapies targeting high-unmet-need indications. The financing was co-led ... |
| 23.01.2026 | Mendra Raises $82M in Series A Funding | Mendra, a San Francisco, CA-based biopharmaceutical company developing therapies for rare disease medicines, raised $82M in Series A funding. The round was co-led by OrbiMed, 8VC, and 5AM Ventures with participation from Lux Capital and Win... |
| - | Mendra | “Mendra is a venture-backed rare-disease biopharma accelerating the development and commercialization of de-risked breakthrough therapies.” |